Samden Lhatoo, MD
Clinical Neurophysiology · Houston, TXNPI 1831411693
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Livanova USA, Inc. at 51.9% of the total. Reporting peaked in 2024 at $41,013 and has fallen 80.9% since, to $7,842 in 2025. Among clinical neurophysiology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $253.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$34K
- UCB, Inc.$9K
- Medtronic$6K
- UCB SA$4K
- Greenwich Biosciences, Inc.$4K
- Neuropace, Inc.$3K
- plus $5K from 16 others
What the payments were for
- Consulting fees$16,15325%
- Speaking & faculty fees$24,25637%
- Travel & lodging$16,53825%
- Food & beverage$8,58313%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 22 | $34,025 |
| UCB, Inc. | 54 | $9,404 |
| Medtronic | 20 | $6,132 |
| UCB SA | 3 | $3,850 |
| Greenwich Biosciences, Inc. | 3 | $3,529 |
| Neuropace, Inc. | 7 | $3,393 |
| SK Life Science, Inc. | 64 | $2,715 |
| Jazz Pharmaceuticals Inc. | 51 | $1,396 |
| Eisai Inc. | 6 | $222 |
| Neurelis, Inc. | 2 | $154 |
| Sumitomo Pharma America, Inc. | 3 | $141 |
| Ceribell, Inc. | 1 | $119 |
| Aucta Pharmaceuticals, Inc. | 6 | $103 |
| Otter Pharmaceuticals, LLC | 3 | $97 |
| Sunovion Pharmaceuticals Inc. | 4 | $64 |
| Abbott | 2 | $44 |
| Catalyst Pharmaceuticals, Inc. | 2 | $34 |
| CSL Behring | 2 | $33 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| AbbVie | 1 | $24 |
| Zogenix Inc. | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$16,227
- VNS Therapy$10,203
- Fintepla$8,970
- VNS Therapy Symmetry Model 8103 Generator$7,212
- Epidiolex$3,960
- RNS Neurostimulator Kit$3,103
- Briviact$1,857
- Nayzilam$127
- XCOPRI$121
- POCKET EEG DEVICE$119
- APTIOM$115
- RNS System$114
How this compares
$65,546 in reported general payments places this provider in the 95th percentile of 50 clinical neurophysiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 43 | $179,395 |
| XcopriCenobamate | 77 | $105,309 |
| BriviactBrivaracetam | 42 | $60,347 |
| VimpatLacosamide | 34 | $51,643 |
| LamictalLamotrigine | 31 | $39,940 |
| NayzilamMidazolam | 25 | $26,059 |
| Trokendi XrTopiramate | 21 | $24,600 |
| ValtocoDiazepam | 11 | $9,396 |
| Levetiracetam | 165 | $9,395 |
| Lacosamide | 107 | $9,355 |
| Lamotrigine ErLamotrigine | 23 | $8,227 |
| Clobazam | 59 | $7,269 |
| Oxcarbazepine | 42 | $6,689 |
| Tegretol XrCarbamazepine | 17 | $5,749 |
| Carbamazepine ErCarbamazepine | 20 | $2,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Vimpat, Nayzilam | $9,404 | $138,048101 claims |
| SK Life Science, Inc.Xcopri | $2,715 | $105,30977 claims |
| Neurelis, Inc.Valtoco | $154 | $9,39611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 50 clinical neurophysiology providers in Texas.
Other clinical neurophysiology in Houston
- Thy NguyenHouston$133K
- Nora Vanegas ArroyaveHouston$82K
- Omotola HopeHouston$63K
- Hina DaveHouston$48K
- Monika UmmatHouston$36K
- Sudha TallavajhulaHouston$14K
- Victor LevinHouston$10K
- Shaun SmartHouston$9K
- Kristin BrownHouston$5K
- Jay GavvalaHouston$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.